ADVFN
Boards:
    Quotes:
      Boards
      News
      Market Data
      Markets
      Discover
      AI Subscribe Login/Register Profile Icon
      S&P 500
      6,296.79
      -0.01%
      US Tech 100
      22,458.00
      -0.06%
      Dow Jones
      44,342.19
      -0.32%
      Brent Oil
      68.685
      0.00%
      Bitcoin
      117,940.01
      -0.08%
      Registration Strip Icon for alerts Register for real-time alerts, custom portfolio, and market movers
      1. Home
      2. Investing
      3. Stocks
      4. USA
      5. NASDAQ
      6. Iovance Biotherapeutics Inc (IOVA)

      7. Iovance Biotherapeutics Inc (IOVA) News

      Iovance Biotherapeutics Inc

      Iovance Biotherapeutics Inc (IOVA)

      NASDAQ
      2.23
      -0.11
      (-4.70%)
      Closed July 19 4:00PM
      Sign in for streaming prices
      2.23
      0.00
      (0.00%)
      After Hours: 7:41PM
      Sign in for streaming prices

      Your Hub for Real-Time streaming quotes, Ideas and Live Discussions

      Premium

      Iovance Biotherapeutics Inc (IOVA) News

      Official News Only

      Form 8-K - Current report
      Edgar (US Regulatory)
      July 15 2025
      IOVA (-4.70%)

      Form 3 - Initial statement of beneficial ownership of securities
      Edgar (US Regulatory)
      July 10 2025
      IOVA (-4.70%)

      Form 8-K - Current report
      Edgar (US Regulatory)
      July 03 2025
      IOVA (-4.70%)

      IOVA Discussion

      View Posts
      surfkast surfkast 2 days ago
      I hope the upward movement is only a precursor of things to come!
      👍 1
      Frankestin Frankestin 2 days ago
      Who will be the first to raise their glass to approval? Will it be the EMA, with its meticulous European touch? Or will the UK and Canada race ahead, fueled by their own regulatory speed? Or maybe Australia will take the crown and leave everyone in the dust!
      👍️0
      surfkast surfkast 3 days ago
      Idiots.
      👍️0
      Sunman88 Sunman88 4 days ago
      Goldman Sachs reduces price target to $1. What a welcome to the new CFO. Her job is cut out. Still praying for a miracle here.
      Q2 earnings will be a revelation. Revenue? Cash position? Cost of goods sold? Demand? 3rd sneaky use of Use of ATM?

      Technology is promising. Logistics is terrible. Financial execution sucks. Demand is behind the curve. Trust is at zero. Interim CEO Vogt has been in interim role for over 2 years. He needs to be fired.

      Run to the ground to facilitate a cheap buyout? Surely appears so. Hope I’m wrong and a miracle takes effect.
      👍️0
      badgerkid badgerkid 4 days ago
      Iovance hires a new CFO, Corleen Roche. Per Ms. Roche: “I am excited to join Iovance to navigate our continued revenue growth and focus our pipeline investments on the highest value opportunities,” stated Ms. Roche. “I am committed to the company’s patient-focused mission while achieving our financial goals to build a profitable biotechnology company.”

      https://ir.iovance.com/news-releases/news-release-details/iovance-biotherapeutics-appoints-corleen-roche-chief-financial

      Here's our new CFO from CG Oncology: https://cgoncology.com/wp-content/uploads/2024/05/Corleen-Roche-CFO.pdf

      Iovance will be another stop on her journey through multiple biotechs. After 30 years, maybe this is her last stop before retirement? Let's hope her experience brings more financial clarity to the company's conference calls and reports.

      GL
      👍️ 1
      Frankestin Frankestin 5 days ago
      looks good... results will come
      The recent real-world data confirm that Amtagvi works effectively in clinical practice, not just in controlled trials. Even more importantly, it shows significantly higher response rates when used earlier in the treatment journey. This could change how physicians manage advanced melanoma after immunotherapy failure and potentially shift the standard of care toward earlier use of TIL therapy.
      👍 3
      badgerkid badgerkid 5 days ago
      New corporate deck: https://ir.iovance.com/static-files/5a1232a2-2137-47d1-92bd-a98cb15aa721

      GL
      👍️ 1
      badgerkid badgerkid 5 days ago
      ORR of 60.9% for Amtagvi. Here's the highlights: "...Response rates with Amtagvi were higher in third-line or earlier patients (two or fewer prior lines of therapy) with an ORR of 60.9% (14/23)."

      Check out today's real world news. Congratulations to Amtagvi. Line up those patients and start improving lives and saving more lives.

      GL to IOVA longs.
      👍️ 3
      badgerkid badgerkid 5 days ago
      Great news to wake up to: "Real-World Data Demonstrate a 49% Response Rate for Commercial Amtagvi® in Patients with Advanced Melanoma"

      https://ir.iovance.com/news-releases/news-release-details/real-world-data-demonstrate-49-response-rate-commercial-amtagvir

      Have a great day!
      👍️ 2
      Structural_Biologist Structural_Biologist 6 days ago
      Great response thank you. I remember we earlier discussed the rigour associated with screening neoantigen reactive TIL for gastric cancer. I didn’t know Dr Rosenberg or any other group was trying to discover a way to quickly identify neoantigen reactive TIL from bulk cultures of tumour fragments.

      Also important to note that even when that method is discovered, it would be several years from being incorporated into Iovance’s workflow.
      👍️ 2
      jondoeuk jondoeuk 1 week ago
      Yes, it is possible now, but identification of neoantigen-reactive TIL for treatment is time- and labour intensive. For example, it takes the US NCI around a month to expand enough TIL just to start screening for reactivity.

      Now Dr. Rosenberg's group (at the US NCI) and others are looking at ways to identify neoantigen-reactive TIL from bulk cultures of tumour fragments without requiring patient-specific testing. If successful, this approach has the potential to greatly decrease the time between resection and treatment.

      Some years ago, one group published data showing certain tumour-reactive CD8+ T-cells are CD39+CD103+. These cells have been found in many solid tumours, including melanoma, NSCLC (high mutational burden), MSS CRC, and pancreatic (low mutational burden) https://www.nature.com/articles/s41467-018-05072-0

      Early data has been presented (from memory, expansion takes around five weeks) https://aacrjournals.org/cancerres/article/84/7_Supplement/LB067/742586/Abstract-LB067-Tumor-reactive-CD8-TIL-with-an
      👍️ 4
      surfkast surfkast 1 week ago
      Lets hope it is stability and forward progress.
      👍 1
      stockyupydowny stockyupydowny 1 week ago
      FORM 3 posted : This shows Rosinack has skin in the game, which can boost investor confidence—especially after the CFO departure and revenue guidance cut.

      The RSUs and options suggest long-term alignment with company performance.

      It’s also a signal that IOVA is stabilizing its leadership team during a critical growth phase.
      👍️ 1
      surfkast surfkast 1 week ago
      Hope it pumps way up again.
      👍️0
      theorysuit theorysuit 1 week ago
      Biotech is mostly pumping across the board.
      👍️0
      surfkast surfkast 1 week ago
      Buyers coming back in?
      👍️0
      surfkast surfkast 1 week ago
      I believe the PPS would depend on what the buyer believes the IOVA portfolio is worth if they could fast track everything with all losses covered.
      👍️ 1
      Sunman88 Sunman88 1 week ago
      Buy out at what price? $3.5 or 5?
      👍 1
      surfkast surfkast 1 week ago
      Our reach seems to be expanding. I believe we need a major player to buy out and run with the program.
      👍 2
      GalacticGuru771 GalacticGuru771 1 week ago
      A patient treated in Singapore!

      https://www.linkedin.com/feed/update/urn:li:activity:7346504091797270528/
      👍️ 2
      Sunman88 Sunman88 2 weeks ago
      $1.70 says it all….beaten down from $18 to $1.70 in one year after Amtagvi approval. Analyze it please.
      Two major dilutions ($400 M+) to raise cash, lies about revenue projection, high cost basis, tough logistics, shrinking demand, etc etc
      They are running out of cash. CFO resigned. Will it go to bankruptcy soon to help a few who have shorted big time and facilitate a cheap transfer to the vultures?
      Only.a miracle will lift it from $1.70 to $18 again. Q2 will reveal its trajectory and seal its fate. Let’s pray for a miracle here.
      👍️0
      surfkast surfkast 2 weeks ago
      Great read. Now I hope this moves back up and draws attention.
      I know there are major money issues, but maybe a buyout from a big bucks company?
      👍️0
      badgerkid badgerkid 2 weeks ago
      Here's a bonus read: https://www.royalmarsden.nhs.uk/news-and-events/news/one-time-cell-therapy-offers-long-term-survival-hope-patients-advanced
      👍️ 1
      surfkast surfkast 2 weeks ago
      I am guessing we have to wait on guidance.
      👍 1
      badgerkid badgerkid 2 weeks ago
      Jondouk, are you actually in the U.K.?

      Let me share a bit of good news from England: I've received confirmation from the NHS that they are preparing for the launch of Lifileucel (Amtagvi) in England, but they are still waiting on a final recommendation from the National Institute for Health and Care Excellence (NICE). My best guess is that Iovance may begin recognizing revenues from the launch of Lifileucel in England as early as Q4 of this year. Proleukin stocking revenues may occur earlier.

      I have not yet received similar confirmations from Northern Ireland, Scotland and Wales as they each authorize independently from England.

      Not necessarily a surprise, but it's good to see that the procurement process has begun in England.

      Hopefully we'll hear something from Iovance regarding other countries and the timing of their launches.

      Good luck to IOVA longs.
      👍️ 1
      badgerkid badgerkid 2 weeks ago
      Total novice here, but I'm curious if you or SB can answer this question: will it eventually be possible to fully select which T-cells are expanded to ensure that the ones grown are the best ones to fight the specific cancer that the patient has? And if so, can this speed up the process even more if they can truly achieve that level of selectivity? My point, no sense expanding the T-cells that don't have an affect on the patient's cancer.

      I'm sure my word choices are inaccurate at best, but I think I'm making my point in these questions.

      TIA

      My depth of knowledge is limited to some of the available articles such as the following: https://www.nature.com/articles/s41392-023-01471-y
      👍️ 1
      jondoeuk jondoeuk 2 weeks ago
      From IOVA's poster: ''Recently, a memory-progenitor stem-like (CD39-CD69-) phenotype was associated with complete regression and TIL persistence in a cohort of patients with metastatic melanoma2'' https://www.iovance.com/uploads/Iovance_ESMO-IO-2021_AKTi-TIL-Expansion.pdf
      👍️ 3
      jondoeuk jondoeuk 2 weeks ago
      I agree with what Badgerkid (and Structural_Biologist) said. Preclinical data from the US NCI https://aacrjournals.org/cancerres/article/75/2/296/606443/Akt-Inhibition-Enhances-Expansion-of-Potent-Tumor
      👍️ 1
      Structural_Biologist Structural_Biologist 2 weeks ago
      Not directly but this patent is related to streamlining the TIL treatment from ~45 days to ~22 days. This is a good step 1. I would like to see another patent related to CD40L and subsequently working to implement that into their workflow to further reduce the manufacturing time.
      👍️ 3
      badgerkid badgerkid 3 weeks ago
      A strong patent portfolio will be a benefit to Iovance in controlling the TIL therapy space, but it's their revenues that will drive the share price. The company has to overcome the loss of trust due to their multiple reiterations of the guidance when they should have been updating and adjusting the guidance to reflect the slower than originally predicted start.

      I believe the company will be just fine over the next 2-3 quarters with each quarter helping to support and ultimately improving the stock's price. But it's all about the revenues at this point as it should be. I think Kirby will prove that he was a very good choice for CCO.

      GL
      👍 2
      surfkast surfkast 3 weeks ago
      New patent. Will it move this? Anyone?
      👍️0
      Frankestin Frankestin 3 weeks ago
      👍️0
      Sunman88 Sunman88 3 weeks ago
      Market at all time high and IOVA at all time low since it’s high of $18 a year ago. What a tragedy! This points to a dishonest (or incompetent or both) leadership and BOD. They have all enabled it to get crushed despite an innovative, first of its kind FDA approved product for end stage melanoma.
      Will it ever recover to $5 and up?
      Based on the confidence shorts are showing, no. However, if Q2 earnings exceed expectations and the conference call is all about honesty (apology offered for incompetence and/or dishonesty) along with announcement of a plan to breakeven by end of 2026 without raising cash at shareholders expense, we may see a recovery. Achievement of milestones with clinical trials and EU approvals will add speed to recovery.
      👍 1
      Sunman88 Sunman88 4 weeks ago
      IOvA may be at $1 or lower before l its full approval. Only thing that matters here is IOVAs ability to cut costs drastically, increase revenue to exceed lowered target and NOT dilute shares at the lows. . This is asking a lot. Q2 will provide a nice glimpse. This stock has been played to the ground. Trust score is close to zero.
      👍 1
      surfkast surfkast 4 weeks ago
      Cutting approval time by months can only be good for IOVA.
      Let's see if the market agrees.
      👍️ 1
      badgerkid badgerkid 4 weeks ago
      Potentially very good news for Iovance and for nsclc and endo approvals:

      https://stocktwits.com/bavariaron/message/618601149

      👍️ 1
      Sunman88 Sunman88 4 weeks ago
      They analysts are a laughing stock. They are so behind the curve. If you bought based on their recommendation, you are screwed now. It’s at $2 for many good reasons. Repeated dilutions to ten time of $400M, lies about annual estimates, demand is low, burn rate is through the roof and additional dilutions are now a strong possibility. If they cannot ramp up sales and beat revised estimates hands down in Q2 and Q3, it’s game
      over. $1 is more likely.
      👍️0
      surfkast surfkast 4 weeks ago
      Based on 12 Wall Street analysts offering 12 month price targets for Iovance Biotherapeutics in the last 3 months. The average price target is $10.00 with a high forecast of $25.00 and a low forecast of $2.00. The average price target represents a 405.05% change from the last price of $1.98.

      7 buy 5 hold 0 sell

      https://www.tipranks.com/stocks/iova/forecast
      👍️0
      Sunman88 Sunman88 1 month ago
      A year ago, post approval for Amtagvi, share price shot up from $9 to $18. Today it is struggling at $2 mostly due to missed revenue, dilution of shares and loss of trust with current management team. CFO leaving at this juncture is proof positive of chaos. Only hope and prayer is the COO delivers on beating revised forecasts for the next several quarters while burn rate is controlled in a manner to reach breakeven by 2026. This coupled with good news from ongoing studies has the potential to bring the stock back to $9 (market cap $3B) by end of this year or early 2026. However, if they miss revised targets, it’s game over. This is my position and I’m sticking to it. Good luck to all of us. We need it to get out of this dire state.
      👍️ 4
      badgerkid badgerkid 1 month ago
      From this point forward, what really matters is improving revenues each and every Q for the next several quarters. Despite what's happened in year one, the new CCO Mr. Kirby and his team have to be fully committed to improving the message of the need to have patients start TIL therapy far earlier in their disease progression. The KOL panel said that very same thing in the fireside chat the other day. There's plenty of catalysts for year two, but increasing revenues has to be at the top of the list by far.

      Some have speculated that the CFO is leaving (or was asked to leave) due to the botched guidance (or the failure in messaging when it became obvious that guidance wasn't going to be met). It's important to remember that the CFO is only one piece in approving guidance before it goes out to the public. Likely the CEO and some BOD members were also part of that decision. If the CFO is being sacrificed, will there be others?

      It's also possible that he's simply moving on as many execs do when they've been in a job for a certain number of years. If they wish to remain relevant, they make those customary job changes multiple times in their careers. Then again, he may simply be going to a job where they understand what he's saying, I always struggled with Jean-Marc's heavy accent on those conference calls.

      In the meantime, IOVA is still a victim of the sector and the overall market until such time that they impress with increasing revenues. Q2 is looking like it'll suffice, but I suspect Q3 will finally show those improvements expected with the new CCO at the helm.

      Many still want additional new leadership and I can't say that I blame them. Bottom line is the bottom line - revenues need to be increasing. Trusting this company's messaging again will take time.

      GL to IOVA longs.
      👍️ 2
      Hicham007 Hicham007 1 month ago
      I am not sure it is a big loss given how they totally missed their FY25 guidance, it might help to restore some confidence between management and shareholders...
      👍️ 4
      surfkast surfkast 1 month ago
      Happens all the time when other opportunities call.
      👍️0
      jondoeuk jondoeuk 1 month ago
      CFO resigned https://www.sec.gov/ix?doc=/Archives/edgar/data/0001425205/000110465925059464/tm2517988d1_8k.htm
      👍️0
      badgerkid badgerkid 1 month ago
      "I was told I'd die from skin cancer - but my tumour disappeared with new therapy": https://inews.co.uk/news/health/skin-cancer-therapy-tumour-disappear-3726365

      “The study demonstrates that for patients with few options left, a single infusion of lifileucel can provide a deep and lasting response and even complete remission in some cases. This marks a major advance in how we think about treating solid tumours.”

      The next step is to help the onc docs to see TIL therapy as an earlier option, as a second line, not end of the line. This has shown to be even far more effective than these good results that we already see when used late in the disease progression.

      Moving toward approval in foreign markets, numerous centers that did trials will become the first ATCs, centers that already have the experience necessary to hit the ground running.

      GL
      👍️ 2
      badgerkid badgerkid 1 month ago
      Jondoeuk, keeping with the goal of limiting off-topic, I chose to remove some posts that open the door to rebuttal. If I let one post stay up, I would need to allow responses which would then take us down that path again that we're trying to avoid.

      Have a great day.
      👍️ 2
      Frankestin Frankestin 1 month ago
      👍️ 1
      badgerkid badgerkid 1 month ago
      Spent a little time digesting the call and the transcript. Dr. Gastman was more conservative and obviously holding back a bit as is necessary when discussing trial data for lung. He can't definitively say without requiring an 8-K, but he most certainly implied that the numbers will be acceptable for the BLA which bodes well for us as shareholders.

      Mr. Kirby was as expected, confident and focused. Exactly what I want from a CCO. Sales and marketing needed a lot more than they had previously and Kirby does seem like the real deal. It all depends on how effective they are at communicating with new docs, ATCs, and the entire medical teams necessary to start driving earlier referrals of patients. 3rd line+ is not going to cut it and they know that full well. Iovance needs more patients and earlier line patients to really impress and get that exponential growth that I believe is fully possible.

      The big takeaway for me is the one we all know, lung is far bigger than the melanoma market, but melanoma is more than enough to be profitable. The slower start did reveal areas that needed attention but are fully correctible for the future success of Iovance. Melanoma was a great place to start and will make future indications pop much quicker upon their approvals now that many of those early bugs are worked out.

      For me, the stock market just doesn't want to reward Iovance's past mistakes until some proof is given over the next couple Q's. Believability is still an issue.

      End of the year should be bangin'.

      GL to IOVA longs.
      👍️ 3
      surfkast surfkast 1 month ago
      Bring back the institutional buyers!

      https://www.tipranks.com/stocks/iova/forecast
      👍️0
      badgerkid badgerkid 1 month ago
      Theorysuit, sorry, but I'm trying to keep off-topic pumping of other companies off this board so I requested removal of the full chain.

      Here's hoping we can keep those types of posts to a minimum.
      👍️ 4
      ducruacuteo11 ducruacuteo11 1 month ago
      This will get all the bulls excited for years to come.
      https://acrobat.adobe.com/id/urn:aaid:sc:VA6C2:8ed05d38-f968-4cc6-a2d7-5db87accc20a
      👍️ 3

      Your Recent History

      NASDAQ
      IOVA
      Iovance Biotherapeutics
      Delayed Upgrade Clock

      Go Ad-Free

      Subscribe to Ad free and enjoy an ad-free experience

      No Ads

      Try Now

      Keep the Ads